Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102570 | 0.93 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5108321 | 0.90 | DRD2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5104617 | 0.85 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5108581 | 0.84 | ESR1 (0.46) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5105659 | 0.84 | ESR1 (0.48) | ALDH1A1 | |
| SCHEMBL5101435 | 0.84 | DRD2 (0.38) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5103435 | 0.82 | ESR1 (0.42) | — | |
| SCHEMBL5108862 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5108476 | 0.82 | DRD2 (0.49) | KMT2AALDH1A1 | |
| SCHEMBL5107746 | 0.82 | LTA4H (0.40) | CCR3CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | SLC6A2 4467/4885SLC6A4 4225/4885SLC6A3 4207/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | SLC6A2 4477/4885SLC6A4 4076/4885SLC6A3 3989/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | SLC6A2 4528/4885SLC6A4 4237/4885SLC6A3 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.